I now have comprehensive material from both the textbook base and the latest evidence (2023-2026). Here's a complete answer.
New Advances in Perianal Fistula Surgery
Traditional treatment of fistula-in-ano balances two competing goals: eradicating the tract versus preserving the anal sphincter and continence. Classic techniques (lay-open fistulotomy for simple/low fistulae, cutting/draining setons, endorectal advancement flaps, LIFT) remain the backbone, but the last decade has produced several sphincter-sparing innovations aimed at improving cure rates while minimizing incontinence risk - Sabiston Textbook of Surgery, p. 2163-2164.
1. Video-Assisted Anal Fistula Treatment (VAAFT)
A fistuloscope is inserted through the external opening to visualize the tract and any side branches directly. The internal opening is closed with suture or staples, granulation tissue is debrided under vision, and the tract is fulgurated with an electrode - all without dividing sphincter muscle. Reported healing rates range 71-85% at up to 2 years, with minimal continence impact - Sabiston Textbook of Surgery, p. 2164.
2. Fistula Laser Closure (FiLaC)
Conceptually similar to VAAFT but uses a radially-emitting laser fiber introduced along the tract to ablate the fistula epithelium from within, rather than electrocautery. A recent meta-analysis reported roughly 65% healing at a median 24-month follow-up - Sabiston Textbook of Surgery, p. 2164. A 2025 network meta-analysis comparing sphincter-sparing techniques (LIFT, laser, ligation-based methods, etc.) confirms laser ablation as a viable low-morbidity option with acceptable failure rates (PMID: 40392371).
3. TROPIS (Transanal Opening of the Intersphincteric Space)
One of the newest and best-supported techniques for high and complex fistulas. It opens the intersphincteric space transanally to deroof the primary infected tract while sparing the external sphincter. A 2025-2026 systematic review/meta-analysis (918 patients) found an overall cure rate of 88%, with 80% success on first attempt (rising with repeat procedures), 87-88% cure even in horseshoe fistulas or those with associated abscess, and low complication rates (3% bleeding, 5% infection) with minimal incontinence risk (PMID: 41537212, 40693967).
4. Anal Fistula Clips (Over-The-Scope Clip, OTSC)
An endoscopically-placed clip approximates and closes the internal opening from inside the anal canal. A 2025 meta-analysis (438 patients) reported a pooled healing rate of 67.7% overall (78.7% for cryptoglandular fistulas), though with a notable complication rate of 30.9%, mainly clip migration/dislodgement (17.3%) - no cases of new fecal incontinence were reported, making it a promising but still-maturing option (PMID: 40929949).
5. Biologic and Regenerative Approaches
- Platelet-rich plasma (PRP): injected into the tract, often combined with flap or plug procedures. A 2023 meta-analysis (514 patients) showed an overall cure rate of 72%, rising to 83% when combined with other surgical treatments, versus lower cure with PRP alone (62%) - superior to non-PRP surgery in RCT data (PMID: 36905475).
- Mesenchymal stem cell (MSC) injection: injected around the fistula tract, particularly studied in Crohn's-related perianal fistulas. Small single-center studies show promising healing, and multiple randomized trials using various stem cell sources are now underway worldwide - Sabiston Textbook of Surgery, p. 2164.
6. Comparative Evidence Landscape (2024-2025)
Recent network meta-analyses have tried to rank these techniques head-to-head:
- A 2025 network meta-analysis of complex cryptoglandular fistula strategies compared flap procedures, LIFT, laser, and clips for failure/incontinence trade-offs (PMID: 40442569).
- A 13-technique network meta-analysis for complex non-Crohn fistulas found sphincter-sparing techniques generally trade a modest reduction in cure rate for a significant reduction in incontinence risk compared to fistulotomy (PMID: 37737881).
- Fistulotomy vs. fistulectomy for simple fistulas remains debated for wound healing time and recurrence (PMID: 40125894).
Practical Takeaway
No single technique has emerged as universally superior. The trend is toward individualized, sphincter-preserving strategies - TROPIS and VAAFT/FiLaC for complex or high tracts, clips or biologics as adjuncts or for select recurrent/Crohn's cases, and fistulotomy retained as the gold standard only for simple, low, non-Crohn's fistulas where incontinence risk is low.
Evidence caveat: Most "advances" above are supported by systematic reviews of single-arm or observational studies rather than large multicenter RCTs; complication and long-term recurrence data are still maturing, particularly for clips and biologic injections (PMID: 40929949, 36905475).